Emmecell
CA - Menlo ParkBiotechnology
Focus: Emmecell is a public-stage biotechnology company focused on cell therapies for ophthalmology, specifically targeting corneal endothelial diseases. The company is headquartered in Menlo Park, CA and operates in a specialized niche of regenerative medicine.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Emmecell
AI assessmentNot HiringNo open roles listed right now. Follow Emmecell to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Emmecell's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
EO2002
Corneal EdemaClinical Trials (2)
NCT07729137Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Phase 2Help build intelligence for Emmecell
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.